Vendor, Burlingame, CA
Phoenix Pharmaceuticals, Inc.
UEI P8XLC937AAK3, CAGE 3F7E4
2 awards and $0 obligated between May 21, 2024 and June 3, 2026.
Industries
NAICS on the awards, by dollars.
| Professional, Scientific, and Technical ServicesNAICS 541711 | $0 |
| Research and Development in Biotechnology (except Nanobiotechnology)NAICS 541714 | $0 |
How it wins
Awards by competition, set-aside and type.
Hear when Phoenix Pharmaceuticals, Inc. wins an award and when a contract it holds is about to end.Follow it
Contracts ending soon
None of Phoenix Pharmaceuticals, Inc.'s contracts with a published end date ends in the next 19 months.
Competes with
Vendors selling professional, scientific, and technical services to National Institutes of Health, by dollars.
| American Foundation for Biological ResearchRockville, MD | $3,565,214 |
| Lundquist Institute for Biomedical Innovation at Harbor-Ucla Medical CenterTorrance, CA | $796,998 |
| Santa Cruz Biotechnology Inc.Dallas, TX | -$5 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75N98024A00126May 21, 2024 | National Institutes of Health OlaoNational Institutes of Health | Biological Materials, Blood/Blood ProductsNAICS 541714, PSC 6505 | $0 |
| HHSN263201500107BMay 22, 2024 | National Institutes of Health OlaoNational Institutes of Health | Biological Materials, Blood/Blood ProductsNAICS 541711, PSC 6505 | $0 |
- Product and service codes
- 6505 Drugs and Biologicals
- Transactions
- 4 across 2 awards